Sophie M. Lanzkron
Expertise in
11
conditions

Dr. Sophie M. Lanzkron

Hematology
1101 Chestnut Street, Floor 8, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
11
conditions
1101 Chestnut Street, Floor 8, 
Philadelphia, PA 

Overview

Sophie Lanzkron is a Hematologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Lanzkron is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Dr. Lanzkron is board certified in Hematology. She is actively involved in clinical research, co-authoring 174 peer reviewed articles and participating in 5 clinical trials. Dr. Lanzkron is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MD

Board Certifications

Hematology

Fellowships

Johns Hopkins University School of Medicine

Hospital Affiliations

The Johns Hopkins Hospital
Thomas Jefferson University Hospital
Thomas Jefferson University Hospital
Jefferson Methodist Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Jefferson Hematology - Honickman Center
1101 Chestnut Street, Floor 8, Philadelphia, PA 19107

Additional Areas of Focus

Dr. Lanzkron has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Sickle Cell Disease

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological, Other
Study Drug: Red Blood Cell
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizuamb
Study Phase: Phase 2
A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health
A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Other, Drug
Study Drug: SHP655
Study Phase: Phase 1
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drug: Riociguat
Study Phase: Phase 2
A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: May 23, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

174 Total Publications

Sickle cell trait does not seal your fate.
Sickle cell trait does not seal your fate.
Journal: Blood
Published: August 20, 2026
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (1.8 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Schuster is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Schuster is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Schuster is board certified in Hematology, 1986, Internal Medicine, 1984, and Medical Oncology, 1989. Dr. Schuster is currently accepting new patients.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (1.8 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stefan Barta is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Barta is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Barta is board certified in Medical Oncology, 2010 and Hematology, 2010. Dr. Barta is currently accepting new patients.

Expertise in
28
conditions
Dr. Adam Cuker
Hematology
Expertise in
28
conditions
Dr. Adam Cuker
Hematology
Referral may be required
Before you request

Penn Blood Disorders Center

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
 (1.8 miles away)
215-615-6555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Cuker is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cuker is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Splenectomy, and Knee Replacement. Dr. Cuker is board certified in Hematology, 2009. Dr. Cuker is currently accepting new patients.

Frequently Asked Questions about Dr. Sophie M. Lanzkron

How do I make an appointment with Dr. Sophie M. Lanzkron?

You can book an appointment with Dr. Sophie M. Lanzkron by calling their office at 215-955-8435. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sophie M. Lanzkron a top-rated expert for Sickle Cell Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sophie M. Lanzkron is classified as an Elite expert for Sickle Cell Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sophie M. Lanzkron specialize in?

While Dr. Sophie M. Lanzkron is a Hematology, they have specific expertise in Sickle Cell Disease, Hemoglobinopathy, and Congenital Hemolytic Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sophie M. Lanzkron participate in research or clinical trials?

Yes. Dr. Sophie M. Lanzkron has published 174 articles and abstracts on conditions like Sickle Cell Disease. You can view a list of Dr. Sophie M. Lanzkron's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sophie M. Lanzkron accept my insurance?

Dr. Sophie M. Lanzkron accepts most major insurance plans, including Aetna and CareFirst. We recommend calling the office directly at 215-955-8435 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lanzkron's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile